Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
These results demonstrate the clinical validity of ultrasensitive ctDNA detection and monitoring using SVs. Prospective trials are required to evaluate ctDNA-guided treatment strategies.
Authors
- Lillian L. Siu (ORCID: https://orcid.org/0000-0002-3500-0540)
- Mitchell J. Elliott (ORCID: https://orcid.org/0000-0001-6711-7287)
- Sasha Main (ORCID: https://orcid.org/0000-0003-2167-8323)
- Lucia Oton (ORCID: https://orcid.org/0000-0002-8515-6754)
- June Roh
- Jesús Fuentes‐Antrás (ORCID: https://orcid.org/0000-0001-5805-2362)
- Miguel Alcaide
- Hal K. Berman (ORCID: https://orcid.org/0000-0001-7524-7911)
- Philippe Lucien Bedard (ORCID: https://orcid.org/0000-0002-6771-2999)
- Sofia Birkeälv (ORCID: https://orcid.org/0000-0001-8192-8334)
- Elizabeth Shah
- Elza C. de Bruin (ORCID: https://orcid.org/0000-0002-8996-8354)
- David W. Cescon (ORCID: https://orcid.org/0000-0002-1080-0998)
- Celeste Yu (ORCID: https://orcid.org/0000-0002-8764-1091)
- Scott V. Bratman (ORCID: https://orcid.org/0000-0001-8610-4908)
- Aaron Dou (ORCID: https://orcid.org/0009-0007-8293-2635)
- Girish Putcha (ORCID: https://orcid.org/0000-0002-6559-620X)
- Karen Howarth (ORCID: https://orcid.org/0000-0002-1124-4583)
- Philippe Echelard (ORCID: https://orcid.org/0000-0002-8586-6473)
- Samuel Woodhouse
- Michelle B. Nadler (ORCID: https://orcid.org/0000-0002-4372-3204)
- Eitan Amir (ORCID: https://orcid.org/0000-0002-3706-525X)
- Taylor Bird
- Christopher Rushton
Institutions
- AstraZeneca (United Kingdom) (GB)
- University Health Network (CA)
- Université de Sherbrooke (CA)
- University of Toronto (CA)
- North Carolina Institute of Medicine (US)
- Princess Margaret Cancer Centre (CA)
- AstraZeneca (Australia) (AU)
- Hospital Universitario Quirónsalud Madrid (ES)
- AstraZeneca (Singapore) (SG)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3472
- Citations
- 17
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 15.92
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Celgene
- Agios Pharmaceuticals
- Break Through Cancer
- Astellas Pharma
- Symphogen
- Genentech
- EMD Serono
- Canadian Cancer Society Research Institute